Tissue engineered skin: Apligraf, a bi-layered living skin equivalent

J. F. Trent, Robert Kirsner

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Driven by the need for a readily available, non-immunological tissue that possesses many of the characteristics of normal human skin, tissue-engineered skin has been developed. For over a decade, laboratory grown or processed skin has been under investigation and, in some cases, available as an alternative to autologous grafts. Apligraf, derived from neonatal foreskin and bovine type I collagen, is the first bi-layered living skin equivalent approved in the US and other countries for use in venous ulcers. Apligraf is effective both in the treatment of refractory venous ulcers and for acute wounds such as surgical excision sites and split thickness donor sites. Apligraf is safe and is not clinically rejected. Its ultimate fate is not known, so it may well work to aid healing in a variety of ways including graft 'take' and as a stimulus for healing.

Original languageEnglish
Pages (from-to)408-413
Number of pages6
JournalInternational Journal of Clinical Practice
Volume52
Issue number6
StatePublished - Sep 1 1998

Fingerprint

Varicose Ulcer
Skin
Transplants
Foreskin
Collagen Type I
Apligraf
Wounds and Injuries

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tissue engineered skin : Apligraf, a bi-layered living skin equivalent. / Trent, J. F.; Kirsner, Robert.

In: International Journal of Clinical Practice, Vol. 52, No. 6, 01.09.1998, p. 408-413.

Research output: Contribution to journalArticle

@article{dd446c19f73b4798a791ac66f31a2a41,
title = "Tissue engineered skin: Apligraf, a bi-layered living skin equivalent",
abstract = "Driven by the need for a readily available, non-immunological tissue that possesses many of the characteristics of normal human skin, tissue-engineered skin has been developed. For over a decade, laboratory grown or processed skin has been under investigation and, in some cases, available as an alternative to autologous grafts. Apligraf, derived from neonatal foreskin and bovine type I collagen, is the first bi-layered living skin equivalent approved in the US and other countries for use in venous ulcers. Apligraf is effective both in the treatment of refractory venous ulcers and for acute wounds such as surgical excision sites and split thickness donor sites. Apligraf is safe and is not clinically rejected. Its ultimate fate is not known, so it may well work to aid healing in a variety of ways including graft 'take' and as a stimulus for healing.",
author = "Trent, {J. F.} and Robert Kirsner",
year = "1998",
month = "9",
day = "1",
language = "English",
volume = "52",
pages = "408--413",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Tissue engineered skin

T2 - Apligraf, a bi-layered living skin equivalent

AU - Trent, J. F.

AU - Kirsner, Robert

PY - 1998/9/1

Y1 - 1998/9/1

N2 - Driven by the need for a readily available, non-immunological tissue that possesses many of the characteristics of normal human skin, tissue-engineered skin has been developed. For over a decade, laboratory grown or processed skin has been under investigation and, in some cases, available as an alternative to autologous grafts. Apligraf, derived from neonatal foreskin and bovine type I collagen, is the first bi-layered living skin equivalent approved in the US and other countries for use in venous ulcers. Apligraf is effective both in the treatment of refractory venous ulcers and for acute wounds such as surgical excision sites and split thickness donor sites. Apligraf is safe and is not clinically rejected. Its ultimate fate is not known, so it may well work to aid healing in a variety of ways including graft 'take' and as a stimulus for healing.

AB - Driven by the need for a readily available, non-immunological tissue that possesses many of the characteristics of normal human skin, tissue-engineered skin has been developed. For over a decade, laboratory grown or processed skin has been under investigation and, in some cases, available as an alternative to autologous grafts. Apligraf, derived from neonatal foreskin and bovine type I collagen, is the first bi-layered living skin equivalent approved in the US and other countries for use in venous ulcers. Apligraf is effective both in the treatment of refractory venous ulcers and for acute wounds such as surgical excision sites and split thickness donor sites. Apligraf is safe and is not clinically rejected. Its ultimate fate is not known, so it may well work to aid healing in a variety of ways including graft 'take' and as a stimulus for healing.

UR - http://www.scopus.com/inward/record.url?scp=0031684903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031684903&partnerID=8YFLogxK

M3 - Article

C2 - 9894378

AN - SCOPUS:0031684903

VL - 52

SP - 408

EP - 413

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 6

ER -